Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy

Sphingosine-1-phosphate receptor (S1P) modulators and anti-CD20 therapies impair humoral responses to SARS-CoV-2 mRNA vaccines. Relatively few studies have assessed the impact of an array of disease modifying therapies (DMTs) for multiple sclerosis (MS) on T cell immune responses to SARS-CoV-2 vacci...

Full description

Saved in:
Bibliographic Details
Published in:EBioMedicine Vol. 73; p. 103636
Main Authors: Gadani, Sachin P., Reyes-Mantilla, Maria, Jank, Larissa, Harris, Samantha, Douglas, Morgan, Smith, Matthew D., Calabresi, Peter A., Mowry, Ellen M., Fitzgerald, Kathryn C., Bhargava, Pavan
Format: Journal Article
Language:English
Published: Netherlands Elsevier B.V 01.11.2021
Elsevier
Subjects:
Adult
Advanced Basic Science
Aged
Antibodies, Monoclonal, Humanized - therapeutic use
COVID-19 - immunology
COVID-19 - prevention & control
COVID-19 - virology
COVID-19 Vaccines - administration & dosage
COVID-19 Vaccines - immunology
Female
Humans
humoral immunity, multiple sclerosis, anti-CD20 therapies
Immunity, Cellular
Immunity, Humoral
Immunologic Factors - therapeutic use
Internal Medicine
Leukocytes, Mononuclear - cytology
Leukocytes, Mononuclear - metabolism
Male
Middle Aged
Multiple Sclerosis - drug therapy
Multiple Sclerosis - pathology
Research Paper
SARS-CoV-2
SARS-CoV-2 - immunology
SARS-CoV-2 - isolation & purification
T cells
Vaccination
T cells
SARS-CoV-2
humoral immunity, multiple sclerosis, anti-CD20 therapies
ISSN:2352-3964, 2352-3964
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sphingosine-1-phosphate receptor (S1P) modulators and anti-CD20 therapies impair humoral responses to SARS-CoV-2 mRNA vaccines. Relatively few studies have assessed the impact of an array of disease modifying therapies (DMTs) for multiple sclerosis (MS) on T cell immune responses to SARS-CoV-2 vaccination. In 101 people with MS, we measured humoral responses via an immunoassay to measure IgG against the COVID-19 spike S1 glycoprotein in serum. We also measured T cell responses using FluoroSpot assay for interferon gamma (IFN-γ) (Mabtech, Sweden) using cryopreserved rested PBMCs and then incubated in cRPMI with 1µg/ml of pooled peptides spanning the entire spike glycoprotein (Genscript, 2 pools; 158 peptides each). Plates were read on an AID iSpot Spectrum to determine the number of spot forming cells (SFC)/106 PBMCs. We tested for differences in immune responses across DMTs using linear models. Humoral responses were detected in 22/39 (56.4%) participants on anti-CD20 and in 59/63 (93.6%) participants on no or other DMTs. In a subset (n=88; 87%), T cell responses were detected in 76/88 (86%), including 32/33 (96.9%) participants on anti-CD20 therapies. Anti-CD20 therapies were associated with an increase in IFN-γ SFC counts relative to those on no DMT or other DMTs (for anti-CD20 vs. no DMT: 425.9% higher [95%CI: 109.6%, 1206.6%] higher; p<0.001; for anti-CD20 vs. other DMTs: 289.6% [95%CI: 85.9%, 716.6%] higher; p<0.001). We identified a robust T cell response in individuals on anti-CD20 therapies despite a reduced humoral response to SARS-CoV-2 vaccination. Follow up studies are needed to determine if this translates to protection against COVID-19 infection. This study was funded partially by 1K01MH121582-01 from NIH/NIMH and TA-1805-31136 from the National MS Society (NMSS) to KCF and TA-1503-03465 and JF-2007-37655 from the NMSS to PB. This study was also supported through the generosity of the collective community of donors to the Johns Hopkins University School of Medicine for COVID research.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally.
Senior Authors.
ISSN:2352-3964
2352-3964
DOI:10.1016/j.ebiom.2021.103636